Ornithine phenylacetate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414537

CAS#: 952154-79-9

Description: Ornithine phenylacetate is an Ammonia Detoxifying Agent

Chemical Structure

Ornithine phenylacetate
CAS# 952154-79-9

Theoretical Analysis

MedKoo Cat#: 414537
Name: Ornithine phenylacetate
CAS#: 952154-79-9
Chemical Formula: C13H20N2O4
Exact Mass: 268.1423
Molecular Weight: 268.31
Elemental Analysis: C, 58.19; H, 7.51; N, 10.44; O, 23.85

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Ornithine phenylacetate; OCR002; OCR m002; OCR-002; LOP; L OP; L-OP

IUPAC/Chemical Name: (S)-2,5-diaminopentanoic acid compound with 2-phenylacetic acid (1:1)


InChi Code: InChI=1S/C8H8O2.C5H12N2O2/c9-8(10)6-7-4-2-1-3-5-7;6-3-1-2-4(7)5(8)9/h1-5H,6H2,(H,9,10);4H,1-3,6-7H2,(H,8,9)/t;4-/m.0/s1

SMILES Code: NCCC[C@@H](C(O)=O)N.OC(Cc1ccccc1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 268.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Jover-Cobos M, Noiret L, Sharifi Y, Jalan R. Ornithine phenylacetate revisited. Metab Brain Dis. 2013 Jun;28(2):327-31. doi: 10.1007/s11011-013-9391-5. Epub 2013 Mar 2. PMID: 23456516.

2: Patidar KR, Bajaj JS. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. Clin Gastroenterol Hepatol. 2015 Nov;13(12):2048-61. doi: 10.1016/j.cgh.2015.06.039. Epub 2015 Jul 9. PMID: 26164219; PMCID: PMC4618040.

3: Hadjihambi A, Arias N, Sheikh M, Jalan R. Hepatic encephalopathy: a critical current review. Hepatol Int. 2018 Feb;12(Suppl 1):135-147. doi: 10.1007/s12072-017-9812-3. Epub 2017 Aug 2. PMID: 28770516; PMCID: PMC5830466.

4: Tapper EB. A Trial of Ornithine Phenylacetate and the Arc of Ammonia's History in the Management of Overt Hepatic Encephalopathy. Clin Gastroenterol Hepatol. 2020 Nov 3:S1542-3565(20)31517-2. doi: 10.1016/j.cgh.2020.11.004. Epub ahead of print. PMID: 33157316.

5: Kornerup LS, Gluud LL, Vilstrup H, Dam G. Update on the Therapeutic Management of Hepatic Encephalopathy. Curr Gastroenterol Rep. 2018 Apr 11;20(5):21. doi: 10.1007/s11894-018-0627-8. PMID: 29644492; PMCID: PMC5895665.

6: Alsahhar JS, Rahimi RS. Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy. Curr Opin Gastroenterol. 2019 May;35(3):145-154. doi: 10.1097/MOG.0000000000000527. PMID: 30893082.

7: Rahimi RS, Safadi R, Thabut D, Bhamidimarri KR, Pyrsopoulos N, Potthoff A, Bukofzer S, Bajaj JS. Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial. Clin Gastroenterol Hepatol. 2020 Oct 16:S1542-3565(20)31432-4. doi: 10.1016/j.cgh.2020.10.019. Epub ahead of print. PMID: 33069881.

8: Alimirah M, Sadiq O, Gordon SC. Novel Therapies in Hepatic Encephalopathy. Clin Liver Dis. 2020 May;24(2):303-315. doi: 10.1016/j.cld.2020.01.009. Epub 2020 Mar 2. PMID: 32245535.

9: Stravitz RT, Gottfried M, Durkalski V, Fontana RJ, Hanje AJ, Koch D, Hameed B, Ganger D, Subramanian RM, Bukofzer S, Ravis WR, Clasen K, Sherker A, Little L, Lee WM; Acute Liver Failure Study Group. Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia. Hepatology. 2018 Mar;67(3):1003-1013. doi: 10.1002/hep.29621. Epub 2018 Jan 30. PMID: 29080224; PMCID: PMC5826861.

10: Zacharias HD, Zacharias AP, Gluud LL, Morgan MY. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis. Cochrane Database Syst Rev. 2019 Jun 17;6(6):CD012334. doi: 10.1002/14651858.CD012334.pub2. PMID: 31204790; PMCID: PMC6572872.